Vertex Pharmaceuticals Incorporated Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (70)

Latest Posts

About This Stock More About This Stock
A Perspective On The Upcoming Calithera Cystic Fibrosis Read-Out
Article By: StockMatusow
Monday, August 2, 2021 8:59 PM EDT
Calithera is guiding for the market to expect what we believe will be a key data read-out in Q3 from its ongoing CB-280 study involving Cystic Fibrosis. A positive read-out here could see a significant upside for the company stock.
In this article: CALA, VRTX Also: INCY
Vertex Pharma Breaks Major Support, Watch This Trade Level
Article By: Nick Santiago
Monday, June 14, 2021 11:20 AM EDT
The next major support level for Vertex Pharma stock will be around the $170.00 area. This is a level where the stock broke out of a major sideways base in October 2019.
In this article: VRTX
2 Must-Own Biotech Stocks To Buy In May
Article By: StockNews
Monday, May 3, 2021 2:42 PM EDT
After a stellar rally in 2020, biotech stocks have been selling off over the past couple of months. This offers investors a buying opportunity to scoop up quality biotech stocks such as Gilead Sciences and Vertex Pharmaceuticals at cheaper prices.
In this article: GILD, VRTX Also: XBI
3 Cathie Wood Healthcare Stocks To Add To Your Portfolio
Article By: StockNews
Saturday, April 24, 2021 7:40 PM EDT
Despite generating lean capital gains on her holdings in the healthcare industry, Cathie Wood has maintained her positions because she expects genomics to emerge as the next big sector in 2021 that could deliver electric vehicle-like gains.
In this article: NVS, REGN, VRTX Also: ARKG
3 Stocks To Buy For The Genomic Revolution
Article By: StockNews
Sunday, April 4, 2021 12:21 PM EDT
The top holdings in Cathie Wood's Ark Genomic Revolution ETF include Novartis , Regeneron Pharmaceuticals and Vertex Pharmaceuticals. The actively managed fund has gained more than 180% over the past year.
In this article: NVS, REGN, VRTX, ARKG

Latest Tweets for $VRTX

No tweets yet!